$NKTR
NEKTAR THERAPEUTICS

2019 Q2 Form 10-Q Financial Statement

#000090670919000006 Filed on August 09, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2
Revenue $23.32M $1.088B
YoY Change -97.86% 3044.69%
Cost Of Revenue $5.018M $5.522M
YoY Change -9.13% -38.57%
Gross Profit $18.30M $1.082B
YoY Change -98.31% 4127.32%
Gross Profit Margin 78.48% 99.49%
Selling, General & Admin $22.60M $20.30M
YoY Change 11.33% 26.88%
% of Gross Profit 123.52% 1.88%
Research & Development $106.7M $88.33M
YoY Change 20.78% 46.59%
% of Gross Profit 583.08% 8.16%
Depreciation & Amortization $3.000M $2.600M
YoY Change 15.38% -39.53%
% of Gross Profit 16.4% 0.24%
Operating Expenses $106.7M $88.33M
YoY Change 20.78% 46.59%
Operating Profit -$111.0M $973.6M
YoY Change -111.4% -2021.98%
Interest Expense $5.231M $5.385M
YoY Change -2.86% -159.18%
% of Operating Profit 0.55%
Other Income/Expense, Net $783.0K $1.745M
YoY Change -55.13%
Pretax Income -$110.2M $975.3M
YoY Change -111.3% -1731.01%
Income Tax $99.00K $3.885M
% Of Pretax Income 0.4%
Net Earnings -$110.3M $971.5M
YoY Change -111.35% -1722.59%
Net Earnings / Revenue -473.03% 89.31%
Basic Earnings Per Share -$0.63 $5.67
Diluted Earnings Per Share -$0.63 $5.33
COMMON SHARES
Basic Shares Outstanding 174.5M shares 171.4M shares
Diluted Shares Outstanding 174.5M shares 182.3M shares

Balance Sheet

Concept 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.515B $1.824B
YoY Change -16.91% 586.93%
Cash & Equivalents $85.42M $911.1M
Short-Term Investments $1.430B $912.7M
Other Short-Term Assets $13.21M $34.90M
YoY Change -62.14% 365.33%
Inventory $13.19M $11.90M
Prepaid Expenses
Receivables $37.30M $35.30M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.597B $1.906B
YoY Change -16.22% 561.31%
LONG-TERM ASSETS
Property, Plant & Equipment $65.45M $45.00M
YoY Change 45.45% -30.66%
Goodwill $76.50M
YoY Change
Intangibles
YoY Change
Long-Term Investments $276.3M $282.3M
YoY Change -2.13% 524.56%
Other Assets $2.400M $3.400M
YoY Change -29.41% 209.09%
Total Long-Term Assets $502.8M $407.2M
YoY Change 23.49% 116.94%
TOTAL ASSETS
Total Short-Term Assets $1.597B $1.906B
Total Long-Term Assets $502.8M $407.2M
Total Assets $2.100B $2.313B
YoY Change -9.23% 386.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.346M $10.70M
YoY Change -12.65% 72.58%
Accrued Expenses $94.10M $58.10M
YoY Change 61.96% 82.13%
Deferred Revenue $9.900M $17.99M
YoY Change -44.96%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $113.4M $96.90M
YoY Change 17.0% 33.47%
LONG-TERM LIABILITIES
Long-Term Debt $247.8M $246.1M
YoY Change 0.69% 0.29%
Other Long-Term Liabilities $643.0K $7.051M
YoY Change -90.88% -95.44%
Total Long-Term Liabilities $643.0K $7.051M
YoY Change -90.88% -98.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $113.4M $96.90M
Total Long-Term Liabilities $643.0K $7.051M
Total Liabilities $542.5M $452.7M
YoY Change 19.84% -4.2%
SHAREHOLDERS EQUITY
Retained Earnings -$1.652B -$1.230B
YoY Change 34.38%
Common Stock $3.210B $3.094B
YoY Change 3.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.557B $1.860B
YoY Change
Total Liabilities & Shareholders Equity $2.100B $2.313B
YoY Change -9.23% 386.04%

Cashflow Statement

Concept 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$110.3M $971.5M
YoY Change -111.35% -1722.59%
Depreciation, Depletion And Amortization $3.000M $2.600M
YoY Change 15.38% -39.53%
Cash From Operating Activities -$53.90M $959.7M
YoY Change -105.62% -1740.51%
INVESTING ACTIVITIES
Capital Expenditures -$11.70M -$2.700M
YoY Change 333.33% 22.73%
Acquisitions
YoY Change
Other Investing Activities $36.90M -$891.7M
YoY Change -104.14% -2117.42%
Cash From Investing Activities $25.30M -$894.4M
YoY Change -102.83% -2229.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.300M 811.0M
YoY Change -99.1% 8527.66%
NET CHANGE
Cash From Operating Activities -53.90M 959.7M
Cash From Investing Activities 25.30M -894.4M
Cash From Financing Activities 7.300M 811.0M
Net Change In Cash -21.30M 876.3M
YoY Change -102.43% -12442.25%
FREE CASH FLOW
Cash From Operating Activities -$53.90M $959.7M
Capital Expenditures -$11.70M -$2.700M
Free Cash Flow -$42.20M $962.4M
YoY Change -104.38% -1809.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Central Index Key
EntityCentralIndexKey
0000906709
nktr Debt Investment Maturity Term
DebtInvestmentMaturityTerm
P1Y
nktr Debt Investment Maximum Maturity Period
DebtInvestmentMaximumMaturityPeriod
P2Y
CY2018Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2019Q2 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0 shares
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
173530000 shares
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
174966000 shares
CY2018Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
CY2018Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2018Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0 USD
CY2019Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0 USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
11963000 USD
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-24006
dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3134940
dei Entity Address Address Line1
EntityAddressAddressLine1
455 Mission Bay Boulevard South
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
482-5300
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
NKTR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
175274453 shares
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85424000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
194905000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1429955000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1140445000 USD
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
37299000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
43213000 USD
CY2019Q2 us-gaap Inventory Net
InventoryNet
13188000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
11381000 USD
CY2019Q2 nktr Advance Payments To Contract Manufacturers
AdvancePaymentsToContractManufacturers
17738000 USD
CY2018Q4 nktr Advance Payments To Contract Manufacturers
AdvancePaymentsToContractManufacturers
26450000 USD
CY2019Q2 us-gaap Other Assets Current
OtherAssetsCurrent
13213000 USD
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
21293000 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
1596817000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
1437687000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
276305000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
582889000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65453000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48851000 USD
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
82177000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4244000 USD
CY2019Q2 us-gaap Assets
Assets
2099653000 USD
CY2018Q4 us-gaap Assets
Assets
2150172000 USD
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
9346000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5854000 USD
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19710000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9937000 USD
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
CY2019Q2 us-gaap Goodwill
Goodwill
76501000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
76501000 USD
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2400000 USD
CY2019Q2 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
29540000 USD
CY2018Q4 nktr Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
14700000 USD
CY2019Q2 nktr Accrued Contract Manufacturing Expense Current
AccruedContractManufacturingExpenseCurrent
23159000 USD
CY2018Q4 nktr Accrued Contract Manufacturing Expense Current
AccruedContractManufacturingExpenseCurrent
23841000 USD
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13830000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9580000 USD
CY2019Q2 us-gaap Interest Payable Current
InterestPayableCurrent
4144000 USD
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4198000 USD
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3749000 USD
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9892000 USD
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13892000 USD
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
113370000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82002000 USD
CY2019Q2 us-gaap Senior Long Term Notes
SeniorLongTermNotes
247821000 USD
CY2018Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
246950000 USD
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
94822000 USD
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2019Q2 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
77813000 USD
CY2018Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
82911000 USD
CY2019Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8029000 USD
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
10744000 USD
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
643000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9990000 USD
CY2019Q2 us-gaap Liabilities
Liabilities
542498000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
432597000 USD
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
17000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
17000 USD
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3210398000 USD
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3147925000 USD
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-788000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6316000 USD
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1652472000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1424051000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
1557155000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1717575000 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2099653000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2150172000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23315000 USD
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1087717000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51537000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1125735000 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5018000 USD
CY2018Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5522000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10458000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12168000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
106686000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88334000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
225149000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
187758000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22581000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20261000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
47587000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38948000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
134285000 USD
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
114117000 USD
us-gaap Costs And Expenses
CostsAndExpenses
283194000 USD
us-gaap Costs And Expenses
CostsAndExpenses
238874000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-110970000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
973600000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-231657000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
886861000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
5231000 USD
CY2018Q2 us-gaap Interest Expense
InterestExpense
5385000 USD
us-gaap Interest Expense
InterestExpense
10457000 USD
us-gaap Interest Expense
InterestExpense
10725000 USD
CY2019Q2 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
5975000 USD
CY2018Q2 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
4975000 USD
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
12040000 USD
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
9994000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11989000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12105000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24472000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13676000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
783000 USD
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1745000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1975000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7043000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-110187000 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
975345000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-229682000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
879818000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-278000 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3885000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1261000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4150000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-109909000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
971460000 USD
us-gaap Net Income Loss
NetIncomeLoss
-228421000 USD
us-gaap Net Income Loss
NetIncomeLoss
875668000 USD
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.27
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.91
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
174549000 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
171378000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
174206000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
166160000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
174549000 shares
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
182291000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
174206000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
178281000 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
87828000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
873777000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1717575000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5463000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25385000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3600000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-107981000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
970254000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-222893000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
34406000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-118512000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
1633511000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7103000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24522000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1928000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-109909000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
1557155000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19949000 USD
CY2018Q1 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
12577000 USD
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-685000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-95792000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
58283000 USD
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
790231000 USD
CY2018Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
20987000 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20659000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1206000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
971460000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
1860414000 USD
us-gaap Profit Loss
ProfitLoss
-228421000 USD
us-gaap Profit Loss
ProfitLoss
875668000 USD
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
17321000 USD
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
15965000 USD
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
12040000 USD
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
9994000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
49907000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40608000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6132000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5115000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
7826000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3991000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5914000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
19557000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1807000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1158000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-15818000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
14282000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3480000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5791000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
9773000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
10717000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
15508000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
15417000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6715000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-6249000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
8701000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
5068000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-134817000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
907176000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
603702000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
989850000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
634145000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
132779000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
11963000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17291000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3730000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2633000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13152000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-846205000 USD
nktr Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
0 USD
nktr Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
790231000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
12200000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
55208000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12200000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
845439000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-16000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-47000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-109481000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
906363000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194905000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4762000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85424000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
911125000 USD
us-gaap Interest Paid Net
InterestPaidNet
9455000 USD
us-gaap Interest Paid Net
InterestPaidNet
9795000 USD
CY2019Q2 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
1800000000 USD
CY2019Q2 us-gaap Senior Notes
SeniorNotes
250000000.0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">assumptions. Our estimates include those related to estimated selling prices of performance obligations and estimates of variable consideration in collaboration agreements, estimated royalty revenue, other estimates required for revenue recognition as described further below, the net realizable value of inventory, the impairment of investments, goodwill and long-lived assets, contingencies, accrued clinical trial, contract manufacturing and other expenses, estimated non-cash royalty revenue and non-cash interest expense from our liability related to our sale of future royalties, stock-based compensation, and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, estimates are assessed each period and updated to reflect current information and any changes in estimates will generally be reflected in the period first identified.</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating income (loss), net income (loss), total assets, liabilities or stockholders’ equity.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Concentrations</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our accounts receivable includes </span><span style="font-family:inherit;font-size:10pt;"><span>$12.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> from contracts with customers and </span><span style="font-family:inherit;font-size:10pt;"><span>$24.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for net expense reimbursements from our collaboration partner Bristol-Myers Squibb. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, our accounts receivable includes </span><span style="font-family:inherit;font-size:10pt;"><span>$24.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> from contracts with customers and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for expense reimbursements from our collaboration partner Bristol-Myers Squibb. We generally do not require collateral from our customers. We perform a regular review of our customers’ credit risk and payment histories, including payments made after period-end. When appropriate, we provide for an allowance for doubtful accounts by reserving for specifically identified doubtful accounts, although historically we have not experienced credit losses from our accounts receivable.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div>
CY2019Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
12900000 USD
CY2018Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
24200000 USD
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
83500000 USD
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
96200000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
400000 USD
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
1500000 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85424000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
194905000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1429955000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1140445000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
276305000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
582889000 USD
CY2019Q2 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
1791684000 USD
CY2018Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
1918239000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
12000000.0 USD
CY2019Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1723828000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1800011000 USD
CY2019Q2 us-gaap Cash
Cash
2294000 USD
CY2018Q4 us-gaap Cash
Cash
5812000 USD
CY2019Q2 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
1791684000 USD
CY2018Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
1918239000 USD
CY2019Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2019Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1757000 USD
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1846000 USD
CY2019Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6961000 USD
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6403000 USD
CY2019Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4470000 USD
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3132000 USD
CY2019Q2 us-gaap Inventory Net
InventoryNet
13188000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
11381000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
2957000 USD
CY2018Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1886000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
5914000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
3724000 USD
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1781000 USD
CY2018Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1182000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
3054000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
2275000 USD
CY2019Q2 us-gaap Lease Cost
LeaseCost
4738000 USD
CY2018Q2 us-gaap Lease Cost
LeaseCost
3068000 USD
us-gaap Lease Cost
LeaseCost
8968000 USD
us-gaap Lease Cost
LeaseCost
5999000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
3100000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4417000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9690000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12671000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13087000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
13515000 USD
CY2019Q2 nktr Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
13956000 USD
CY2019Q2 nktr Lessee Operating Lease Liability Payments Due After Year Six
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix
78233000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
145569000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
43021000 USD
CY2019Q2 nktr Lessee Operating Lease Liability Tenant Improvement Reimbursements
LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
3977000 USD
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
98571000 USD
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3749000 USD
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
94822000 USD
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y7M6D
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
17300000 USD
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
16000000.0 USD
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
12000000.0 USD
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
10000000.0 USD
nktr Estimated Annual Interest Rate Over Life Of Royalty Liability
EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
0.17
CY2017Q4 nktr Estimated Annual Interest Rate Over Life Of Royalty Liability
EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
0.176
CY2017Q4 nktr Prospective Interest Rate Percentage
ProspectiveInterestRatePercentage
0.21
CY2018Q4 nktr Estimated Annual Interest Rate Over Life Of Royalty Liability
EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
0.187
CY2018Q4 nktr Prospective Interest Rate Percentage
ProspectiveInterestRatePercentage
0.29
CY2019Q2 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
2535000 USD
CY2018Q2 nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
1064246000 USD
nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
6739000 USD
nktr License Collaboration Other Revenue
LicenseCollaborationOtherRevenue
1077973000 USD
CY2019Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
16400000 USD
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
36100000 USD
CY2018Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
17600000 USD
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
45600000 USD
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
24636000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
6715000 USD
CY2019Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
17921000 USD
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9900000 USD
CY2019Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8000000.0 USD
CY2019Q2 nktr Potential Development And Regulatory Milestones
PotentialDevelopmentAndRegulatoryMilestones
1700000000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24522000 USD
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20659000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
49907000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40608000 USD
CY2019Q2 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
738538 shares
CY2018Q2 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
1750908 shares
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
1436538 shares
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
4605724 shares
CY2018Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10900000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
12100000 shares
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3200000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3100000 shares

Files In Submission

Name View Source Status
0000906709-19-000006-index-headers.html Edgar Link pending
0000906709-19-000006-index.html Edgar Link pending
0000906709-19-000006.txt Edgar Link pending
0000906709-19-000006-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nktr-20190630.xsd Edgar Link pending
nktr-20190630_cal.xml Edgar Link unprocessable
nktr-20190630_def.xml Edgar Link unprocessable
nktr-20190630_lab.xml Edgar Link unprocessable
nktr-20190630_pre.xml Edgar Link unprocessable
nktr2019-06x30x10q.htm Edgar Link pending
nktr2019-06x30x10q_htm.xml Edgar Link completed
nktr2019-06x30xexx311.htm Edgar Link pending
nktr2019-06x30xexx312.htm Edgar Link pending
nktr2019-06x30xexx321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending